Ask AI
Targeted Agents in Relapsed ES SCLC

CE / CME

Translating Evidence to Action in Relapsed ES-SCLC: Integrating New Targeted Agents Into Clinical Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 25, 2025

Expiration: May 24, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 56-year-old patient with a history of chronic obstructive pulmonary disease was diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) 6 months ago and received first-line etoposide, carboplatin, and durvalumab for 4 cycles, followed by 3 months of durvalumab maintenance. A PET scan after the third cycle of maintenance showed progressive disease (PD) with new lymph node, chest wall, and liver metastases. MRI reveals 2 subcentimeter, asymptomatic brain metastases. The patient has an Eastern Cooperative Oncology Group performance status of 0, adequate labs, and no symptoms.

Which of the following systemic treatment options would you select for this platinum-refractory patient?

2.

In the phase Ib DAREON-9 trial evaluating obrixtamig combined with topotecan for relapsed SCLC, which of the following outcomes was observed?